Chemerin: A Novel Adipokine as a Predictor for Coronary Arery Disease in Patients with Metabolic Syndrome

Thesis

Submitted for Partial Fulfillment of Master Degree

In

Clinical and Chemical Pathology

By

Noha Mohammed Hussien Mohammed

M.B., B.Ch., Ain Shams University

Under Supervision of

Professor/ Manal Mohamed Abdel Aziz

Professor of Clinical and Chemical Pathology Faculty of Medicine- Ain Shams University

Doctor/ Ayman Morttada Abd El- Moteleb

Assistant Professor of Cardiology Faculty of Medicine - Ain Shams University

Doctor/ Hoda Ahmed Abd Elsattar

Lecturer of Clinical and Chemical Pathology Faculty of Medicine - Ain Shams University

Faculty of Medicine
Ain Shams University
2014





First of all, all gratitude is to **Allah** for blessing this work, until it has been successfully completed, one of his generous help, throughout my life.

Really I can hardly find the words to express my sincere gratitude to **Prof.** Manal Mohamed Abdel Aziz Professor of Clinical and Chemical Pathology, faculty of medicine, Ain Shams University, for her supervision, continuous help, encouragement throughout this work and great effort she has done in the meticulous revision of the whole work. It is a great honor to work under her guidance and supervision.

I am also grateful to **Dr. Ayman Morttada Abd El-Moteleb** Assistant Professor of Cardiology, faculty of medicine, Ain Shams University for his guidance, continuous assistance, sincere supervision, great support, kind advices and valuable suggestion.

I would like also to express my sincere appreciation and gratitude to **Dr. Hoda Ahmed Abd Elsattar**, Lecturer of Clinical and Chemical Pathology, faculty of medicine, Ain Shams University, for her continuous directions and instructive supervision, encouragement, unlimited support and for offering me much of her time and effort.

Noha Mohammed Hussien Mohammed





I would like to dedicate this Thesis to my great FAMILY; to them I will never find adequate words to express my gratitude.

Also to my **Husband** for his continuous support, guidance and patience during this work

Table of Contents

| List o | of Abbreviations | IV |
|-----------|---|------|
| List o | of Tables | VIII |
| List o | of Figures | X |
| Intro | oduction | 2 |
| Aim (| of the Work | 5 |
| I. | Metabolic Syndrome | 7 |
| A. | Brief History: | 7 |
| В. | Definitions of the Metabolic Syndrome: | 7 |
| C. | . Epidemiology and Prevalence of the Metabolic Syndrome: | 10 |
| D. | . Pathophysiology of the Metabolic Syndrome: | 11 |
| | 1. Insulin resistance theory: | 12 |
| | 2. Genetic theory: | 15 |
| | 3. Other genetic factors: | 17 |
| E. | Laboratory Diagnosis of Metabolic Syndrome: | 18 |
| | 1. Fasting plasma glucose: | 19 |
| | 2. Triglycerides: | 19 |
| | 3. High-density lipoprotein cholesterol: | 20 |
| | 4. Pro-inflammatory molecules: | 21 |
| F. | Metabolic Syndrome and Coronary Artery Disease: | 44 |
| | 1. Epidemiology: | 45 |
| | 2. Correlation between metabolic syndrome and coronary an | _ |
| | disease: | |
| II. | CHEMERIN | |
| A. | | |
| В. | | |
| C. | . Distribution: | 51 |

Table of Contents (Cont.)

| D. | Act | ivation: | . 53 |
|-------|--------|--|------|
| E. | Phy | siological Role of Chemerin: | . 54 |
| F. | Patl | hophysiological Role: | . 58 |
| | 1. | Chemotaxis and inflammation: | . 58 |
| | 2. | Obesity and metabolic syndrome: | . 59 |
| | 3. | Atherosclerosis: | 60 |
| | 4. | Diabetes mellitus: | 61 |
| | 5. | Psoriasis: | 63 |
| | 6. | Tumors' biomarker: | 64 |
| G. | Dia | gnostic Value of Chemerin: | 65 |
| | 1. | Diabetes Mellitus: | 65 |
| | 2. | Hypertension: | 65 |
| | 3. | Diabetic Nephropathy: | . 66 |
| Н. | Met | thods of Assay: | . 67 |
| | 1. | Reverse transcriptase polymerase chain reaction: | 67 |
| | 2. | Western blot technique: | 69 |
| | 3. | Enzyme linked immunosorbent assay: | . 71 |
| Subje | ects a | nd Methods | . 74 |
| A. | Sub | jects: | . 74 |
| | 1. | Group I (Patients' Group; n=60): | . 74 |
| | 2. | Group II (Healthy Control Group; n=30): | . 75 |
| В. | San | nples: | . 76 |
| C. | Met | hods: | . 76 |
| | 1. | Analytical Methods: | . 76 |
| | 2. | Statistical Methods: | 83 |
| | | | |

Table of Contents (Cont.)

| Results | 96 |
|------------------------|-----|
| Discussion | 129 |
| Summary and Conclusion | 140 |
| Recommendations | 144 |
| References | 146 |
| Arabic Summary | |

List of Abbreviations

AHA : American heart association.

ANOVA : Analysis of variance
 Apo A1 : Apolipoprotein a1
 Apolipoprotein b
 AS : Aortic stenosis

AT1-R : Angiotensin 1 receptor **ATP** : Adenosine triphosphate

AUC : Area under the receiver operating characteristic

curve

BMI : Body mass index.BP : Blood pressure

CABG : Coronary artery bypass grafting

CAD : Coronary artery disease

c-AMP : Cyclic adenosine monophosphate

CCRL2 : Chemokine receptor like 2CD : Cluster of differentiation.

cDNA : Complementary dna.CE : Cholesterol esteraseChemR23 : Chemerin receptor 23

CMKLR1 : Chemokine-like receptor 1.

CRP : C-reactive protein.

CV : Coefficient of variationCVD : Cardiovascular diseases

DCs : Dendritic cells

DNA : Deoxyribonucleic acid

dNTPs : Thermostable polymerase deoxynucleotides

EAT : Epicardial adipose tissue

List of Abbreviations (Cont.)

EGIR : European group for the study of insulin

resistance

ELISA : Enzyme linked immunosorbent assay **ELISA** : Enzyme linked immunosorbant assay

ERK 1/2 : Extracellular signal regulated kinase 1 and 2

FBG: Fasting blood glucose

FFAs : Free fatty acidsFN : False negativeFP : False positive

FTO : Fat mass and obesity–associated gene

GPR1 : G protein coupled receptor 1

HDL-C: High-density lipoprotein cholesterol

HMGB1 : High-mobility group protein b1

HMWR : High molecular weight adiponectin / total

adiponectin ratio

HOMA-IR: Homeostatic model assessment of insulin

resistance

hsCRP : High-sensitivity c-reactive protein

HSPs: Heat shock proteins

IDF : International diabetes federation

IFG : Impaired fasting glucoseIGT : Impaired glucose tolerance

IL-10: Interleukin 10IL-18: Interleukin 18IL-1β: Interleukin 1βIL-6: Interleukin-6

INF-γ : Interferon gammaIQR : Interquartile rangeIR : Insulin resistance

List of Abbreviations (Cont.)

IRS-1 : Insulin receptor substrate-1

KDa : Kilodaltons

LDL-C: Low-density lipoprotein-cholesterol

Lp (a) : Lipoprotein a

MCP-1 : Monocyte chemotactic protein 1MDM : Monocyte derived macrophages

MMPs : Matrix metalloproteinasesmRNA : Messenger ribonucleic acid

MS: : Metabolic syndrome

N : Number

NCEP- : National cholesterol education program- adult

ATP III treatment panel iii

NCP : Nitrocellulose paper.

NHLBI : National heart lung and blood institute

NK : Natural killer

NPV : Negative predictive value

Ox-LDL : Oxidized ldl.

PAI-1 : Plasminogen activator inhibitor 1
PPV : Predictive value for a positive test
RAAS : Renin angiotensin-aldosterone system

RELM-β : Interleukin-2receptor **RETN** : Resistin coding gene

ROC : Receiver-operating characteristic

ROS : Reactive oxygen species.

RT-PCR : Reverse transcriptase polymerase chain reaction

SD : Standard deviation

SSC : Skin squamous cell carcinoma

T.Ch: Total cholesterol

List of Abbreviations (Cont.)

T2DM: Type 2 diabetes mellitus

TCF7L2 : Transcription factor seven-like two

TG: Triglycerides
Th-1: T helper 1

tHcy : Total homocysteine.

TIG2 : Tazarotene-induced gene 2

TN : True negative

TNF-a : Tissue necrosis factor alphatPA : Tissue plasminogen activatorVLDL : Very low-density lipoprotein

Vs : Versus.

WC : Waist circumference

WHO: : World health organization

List of Tables

| TABLE 1: Various Definitions Of The Metabolic Syndrome 9 |
|---|
| TABLE 2: Demographic Data Of The Studied Parameters |
| TABLE 3: Sex Differences Between Patient Group And Control Group Using Chi-Squared Test |
| TABLE 4: Comparative Statistics Between The Three Studied Groups Regarding Demographic Data Using ANOVA Test For Parametric Data And Kruskall Wallis Test For Non Parametric Data |
| TABLE 5: Descriptive And Comparative Statistics Of Measured Laboratory Data Of Studied Parameters Using Mann-Whitney Test |
| TABLE 6: Descriptive And Comparative Statistics Between The Three Studied Groups Regarding Different Studied Laboratory Parameters Using Kruskall Wallis Test |
| TABLE 7: Comparative Statistics Between The Three Studied Groups Regarding Different Studied Laboratory Parameters Using Mann-Whitney Test 110 |
| TABLE 8: Correlation Study Between Chemerin And The Other Studied Parameters In Subgroup Ia Using Pearson Correlation Coefficient Test And Spearman's Rank Correlation Coefficient |
| TABLE 9: Correlation Study Between Chemerin And The Other Studied Parameters In Subgroup Ib Using Pearson Correlation Coefficient Test And Spearman's Rank Correlation Coefficient |
| TABLE 10: Correlation Study Between Chemerin And The Other Studied Parameters In Group (II) Using Pearson Correlation Coefficient Test And Spearman's Rank Correlation Coefficient |

List of Tables (Cont.)

| TAB | LE 11: Calculated Z Score For Different Studied Laboratory Parameters In |
|-----|---|
| | Group I, Subgroup Ia And Subgroup Ib In Comparison To Control Group |
| | |
| TAB | LE 12: Calculated Z Score For Different Studied Laboratory Parameters In |
| | Subgroup Ia Vs Subgroup Ib |
| | LE 13: Diagnostic Performance Of Chemerin In Discrimination Group I And Group II Using Receiver Operating Characteristics (Roc) Curve Analysis 124 |
| | LE 14: Diagnostic Performance Of Chemerin In Discrimination Subgroup Ia And Group II Using Receiver Operating Characteristics (Roc) Curve Analysis 125 |
| | LE 15: Diagnostic Performance Of Chemerin In Discrimination Subgroup Ib And Group II Using Receiver Operating Characteristics (Roc) Curve Analysis 126 |
| | LE 16: Diagnostic Performance Of Chemerin In Discrimination Subgroup Ia And Subgroup Ib Using Receiver Operating Characteristics (Roc) |

List of Figures

| FIGURE 1: Proposed Mechanisms For The Clustering Of MS Traits And The Increased |
|---|
| Risk Of T2DM And Cardiovascular Disease (CVD)14 |
| FIGURE 2: Simplified Hypothetical Diagram Of The Metabolic Syndrome |
| FIGURE 3: Pro-Inflammatory Molecules And The Metabolic Syndrome22 |
| FIGURE 4: Pathophysiology Of Atherosclerosis In The Metabolic Syndrome 48 |
| FIGURE 5: Structure Of Chemerin. 51 |
| FIGURE 6: Role Of Chemerin And CMKLR1 In Adipose Tissue Biology55 |
| FIGURE 7: Regulation Of Chemerin Actions By Active, Pro-Inflammatory Chemerin |
| And Inhibitory Chemerin-Derived Peptides57 |
| DIGITAL D. I. C. I. D. I. (DELDOD) |
| FIGURE 8: Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)68 |
| FIGURE 8: Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) |
| |
| FIGURE 9: Western Blot Method |

List of Figures (Cont.)

| FIGURE 17: Boxplot Between Groups As Regard Chemerin Conc. (ng/mL) 107 |
|--|
| FIGURE 18: Boxplot Between Groups As Regard HDL-C/T.Ch%107 |
| FIGURE 19: Boxplot Between Groups As Regard T.Ch/HDL-C ratio |
| FIGURE 20: Boxplot Between Groups As Regard LDL-C /HDL-C ratio108 |
| FIGURE 21: Boxplot Between Three Groups As Regard TG (mg/dL)111 |
| FIGURE 22: Boxplot Between Three Groups As Regard T.Ch (mg/dL)111 |
| FIGURE 23: Boxplot Between Three Groups As Regard HDL-C (mg/dL)112 |
| FIGURE 24: Boxplot Between Three Groups As Regard LDL-C (mg/dL)112 |
| FIGURE 25: Boxplot Between Three Groups As Regard Chemerin Conc. (ng/mL)113 |
| FIGURE 26: Boxplot Between Three Groups As Regard HDL-C /T.Ch%113 |
| FIGURE 27: Boxplot Between Three Groups As Regard T.Ch/HDL-C114 |
| FIGURE 28: Boxplot Between Three Groups As Regard LDL-C/HDL-C114 |
| FIGURE 29: Correlation Between Chemerin Conc. (ng/mL) and BMI in Subgroup Ia. |
| FIGURE 30: Correlation Between Chemerin Conc. (ng/ml) and T.Ch (mg/dl) in |
| Subgroup Ia |
| FIGURE 31: Correlation Between Chemerin Conc. (ng/mL) and LDL-C (mg/dL) in Subgroup Ia |
| FIGURE 32: Correlation Between Chemerin Conc. (ng/mL) and BMI in Subgroup Ib |
| 119 |